Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Comment by gainwidpatienceon May 13, 2021 1:11pm
122 Views
Post# 33195399

RE:RE:RE:Q3 Report - 13 May

RE:RE:RE:Q3 Report - 13 May They never made any attempt to increase investor awareness over these years. There are hardly anyone talking about this company on social media. So, the question is how this stock has 80k average volume everyday and who is controlling the sp. They didn't seem to be bothered about sp being low during the last webinar. It looks like they are very happy with the money in the bank and they can relax for next 1 year. They know how to convince the shareholders who are making noise.. just like they released 3 NR and people are happy without thinking that it hardly made any impact on sp.. most of us are down with huge amount.
<< Previous
Bullboard Posts
Next >>